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Abstract
Introduction: Anti-endothelial cell antibodies (AECAs) are thought to be critical for vasculitides in collagen
diseases, but most were directed against molecules localized within the cell and not expressed on the cell surface.
To clarify the pathogenic roles of AECAs, we constructed a retroviral vector system for identification of
autoantigens expressed on the endothelial cell surface.
Methods: AECA activity in sera from patients with collagen diseases was measured with flow cytometry by using
human umbilical vein endothelial cells (HUVECs). A cDNA library of HUVECs was retrovirally transfected into a rat
myeloma cell line, from which AECA-positive clones were sorted with flow cytometry. cDNA of the cells was
analyzed to identify an autoantigen, and then the clinical characteristics and the functional significance of the
autoantibody were evaluated.
Results: Two distinct AECA-positive clones were isolated by using serum immunoglobulin G (IgG) from a patient
with systemic lupus erythematosus (SLE). Both clones were identical to cDNA of fibronectin leucine-rich
transmembrane protein 2 (FLRT2). HUVECs expressed FLRT2 and the prototype AECA IgG bound specifically to
FLRT2-transfected cells. Anti-FLRT2 antibody activity accounted for 21.4% of AECAs in SLE. Furthermore, anti-FLRT2
antibody induced complement-dependent cytotoxicity against FLRT2-expressing cells.
Conclusions: We identified the membrane protein FLRT2 as a novel autoantigen of AECAs in SLE patients by using
the retroviral vector system. Anti-FLRT2 antibody has the potential to induce direct endothelial cell cytotoxicity in
about 10% of SLE patients and could be a novel molecular target for intervention. Identification of such a cell-
surface target for AECAs may reveal a comprehensive mechanism of vascular injury in collagen diseases.
Introduction
Vascular endothelial cells (ECs) represent the boundary
between blood and tissue, and contribute to the process
of inflammation. Anti-endothelial cell antibodies
(AECAs) were first described in 1971 and defined as
autoantibodies that target antigens present on the EC
membrane [1,2]. AECAs have been detected in a num-
ber of patients with collagen diseases, including systemic
lupus erythematosus (SLE), and were shown to be corre-
lated to disease activity [3,4]. SLE is one of the diseases
in which AECAs are frequently detected, and they are
considered to play a role in the pathogenesis, especially
in lupus nephritis [3,4]. In addition, SLE patients have
an increased risk of cardiovascular disease originating
from SLE itself, and it has been reported that AECAs
play roles in atherosclerotic events [5].
AECAs have the potential to induce vascular lesions
directly because their targets are expressed on ECs,
which are always in contact with these circulating anti-
bodies. AECAs are considered to play roles in the
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development of pathologic lesions by EC cytotoxicity
(complement-dependent cytotoxicity (CDC) and anti-
body-dependent cell-mediated cytotoxicity (ADCC)),
activation of EC (proinflammatory cytokine secretion
and expression of adhesion molecules), induction of
coagulation, and induction of apoptosis [6-9].
Although new biologic drugs have been applied to the
treatment of SLE, currently available therapies often
introduce the additional risk of immunosuppression
[10]. Bloom et al. [11] proposed a model for customized
and specific therapeutic approaches against a highly
pathogenic subset of lupus antibodies by using small
molecules that neutralize them. AECAs may be good
targets for such interventions, and identification of cell-
surface targets of AECAs is required.
Target antigens of AECAs had been investigated inten-
sively, but they are heterogeneous and classified into the
following three groups: membrane component, ligand-
receptor complex, and molecule adhering to the plasma
membrane [12]. The cellular localization of the target anti-
gen is considered to be a critical factor in the pathogenesis
of autoantibodies [13], and it is generally accepted that
autoantibodies against integral membrane proteins are
usually pathogenic [14]. Although AECAs must be direc-
ted against the cell surface, most of the molecules reported
to date as targets for AECAs are intracellular proteins
[2,4,6,15]. Several groups have recently identified targets of
AECAs by proteomics analysis [16,17]. However, extrac-
tion of some membrane proteins is difficult in proteomics
analysis, and this may be one of the reasons that such pro-
teins were not identified as AECA targets [2].
We constructed a retroviral vector system [18] to iden-
tify autoantigens expressed on the EC surface by using
flow cytometry and identified the membrane protein fibro-
nectin leucine-rich transmembrane protein 2 (FLRT2) as a
novel autoantigen of AECAs in patients with SLE.
Materials and methods
Sources of human sera
Two hundred thirty-three patients with collagen diseases
(196 female and 37 male patients) were enrolled in the
study. The mean age was 42.5 years, with a range of 18 to
72 years. The patients comprised 95 with SLE and 138
with other collagen diseases. All of the patients were diag-
nosed according to the respective classification criteria
[19-32]. Thirty-five age- and sex-matched healthy donors
were enrolled as a control group. Sera were collected and
stored at -20°C until use. All subjects gave written consent
after the purpose and potential risks involved in the study
were explained. The study protocol complied with the
principles of the Declaration of Helsinki and was approved
by the Ethical Committee of Tohoku University Graduate
School of Medicine.
Cell culture
Human umbilical vein endothelial cells (HUVECs), human
aortic endothelial cells (HAECs), human lung microvascu-
lar endothelial cells (HMVEC-Ls), and EGM-2 medium
were purchased from Lonza (Basel, Switzerland). Human
renal glomerular endothelial cells (HRGECs) and endothe-
lial cell medium were purchased from ScienCell Research
Laboratories (Carlsbad, CA, USA). The cells were grown
in 5% CO2 at 37°C on polystyrene flasks (BD Biosciences,
Bedford, MA, USA). These ECs were used at sooner than
the fifth passage. HEK293T cells were purchased from
American Type Culture Collection (ATCC) (Manassas,
VA, USA), Plat-E and Plat-GP packaging cells were pur-
chased from Cell Biolabs (San Diego, CA, USA) and cul-
tured in Dulbecco modified Eagle medium (DMEM)
(Sigma, St. Louis, MO, USA) supplemented with 10% fetal
bovine serum (FBS) (HyClone, Logan, UT, USA). Rat mye-
loma cells, YB2/0, were purchased from ATCC and cul-
tured in RPMI1640 medium (Sigma) containing 10% FBS.
IgG purification
IgG fractions were purified from sera by using HiTRAP
Protein G HP columns (Amersham Biosciences, Roosen-
daal, The Netherlands). The concentration of purified
IgG was determined by measuring the OD at 280 nm
(OD280). Purified IgG was stored at -20°C until use.
Flow cytometry
Binding activities of antibodies to the surface of ECs and
FLRT2 molecules were measured by using FACSCalibur
and FACSCanto II (Becton Dickinson, Franklin Lakes, NJ,
USA) [17], and the data were analyzed with FlowJo Soft-
ware (Tree Star, Ashland, OR, USA). In brief, attached
cells were dissociated from plates by using Cell Dissocia-
tion Solution (Sigma) and washed with phosphate-buffered
saline (PBS). Aliquots of 1 × 105 cells/tube were incubated
in blocking buffer (PBS containing 1% bovine serum albu-
min and 50 mg/ml goat gamma globulin fraction (Sigma))
with primary antibodies at 4°C for 30 minutes. After wash-
ing, cells were incubated with secondary antibodies and
7-amino-actinomycin D (7-AAD) (BD Biosciences) at 4°C
for 30 minutes and analyzed with flow cytometry.
Primary antibodies included 1:10 diluted human serum,
0.5 mg/ml of purified human IgG, and 10 μg/ml goat anti-
human FLRT1/FLRT2/FLRT3 antibody (R&D Systems,
Minneapolis, MN, USA). Secondary antibodies included
1:50 diluted fluorescein isothiocyanate (FITC) or phycoer-
ythrin (PE)-conjugated goat anti-human IgG (Abcam,
Cambridge, UK), PE-conjugated donkey anti-goat IgG
(Abcam), PE-conjugated mouse anti-human IgG1/IgG2/
IgG3/IgG4 antibody (Beckman Coulter, Fullerton, CA,
USA), and DyLight 650-conjugated anti human IgM anti-
body (Abcam). For staining of the intracellular FLRT2
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domain, IntraStain (Dako, Glostrup, Denmark) and anti-
human FLRT2 antibody (K-20) (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) were used.
For measurement of AECA activity, the relative mean
fluorescence intensity (MFI) ratio was calculated as fol-
lows: (sample MFI - control MFI)/control MFI × 100 [33].
Relative MFI ratio of mean + 3 standard deviations (SD)
among the control group was defined as the cutoff value
for AECAs. For measurement of anti-FLRT2 activity
against the cell-surface domain, the relative MFI ratio was
calculated as follows: (MFI against FLRT2-expressing cells
- MFI against non-FLRT2-expressing cells)/MFI against
non-FLRT2-expressing cells × 100. In each set of experi-
ments, relative MFI ratios of titrated reference serum with
high anti-FLRT2 activity were calculated, and a standard
curve was generated. The relative MFI ratio was converted
to arbitrary units (AUs) according to the standard curve.
AU of mean + 3 SD in the control group was defined as
the cutoff value for the anti-FLRT2 antibody. Recombinant
human FLRT2 (R&D Systems) was added at the indicated
dose in inhibition tests. The percentage inhibition was cal-
culated as follows: % inhibition = (AECA titer of sample
serum - AECA titer of sample serum with inhibitor)/
AECA titer of sample serum × 100.
HUVEC cDNA library
Total RNA was generated from HUVECs by using an
RNeasy Mini Kit (Qiagen, Hilden, Germany), and poly(A)
+ RNA was purified with an mRNA Purification Kit (GE
Healthcare, Little Chalfont, Buckinghamshire, UK). Dou-
ble-stranded cDNA was synthesized by using a cDNA
library construction kit (Takara Bio, Shiga, Japan). DNA
fragments > 1,000 bp in length were ligated into the pMX
vector (kindly donated by Toshio Kitamura, University of
Tokyo, Tokyo, Japan).
Screening of cDNA library
The HUVEC cDNA library in pMX was retrovirally trans-
fected into the YB2/0 rat myeloma cell line [34]. Aliquots
of 1 × 107 YB2/0 cells expressing the HUVEC cDNA
library were incubated with 0.5 mg/ml of IgG with high
AECA activity at 4°C for 30 minutes. After washing, cells
were incubated with FITC-conjugated goat anti-human
IgG and 7-AAD at 4°C for 30 minutes. The cells showing
a high level of FITC fluorescence signal were sorted with
FACS Vantage (Becton Dickinson). Sorted cells were kept
in culture until the cell number increased sufficiently for
the next round of sorting. Subcloning of cells bound to
IgG with AECA activity was performed by the limiting
dilution method.
Genomic DNAs of clones were purified by using the
Wizard SV Genomic DNA Purification system (Promega
Corporation, Madison, WI, USA). DNA fragments from
the HUVEC cDNA library were amplified by polymerase
chain reaction (PCR) by using TaKaRa LA Taq (Takara
Bio) with primers corresponding to the 5’ and 3’ ends of
the multiple cloning site of pMX (5’-GGTGGAC-
CATCCTCTAGACTG, 3’-CCTTTTTCTGGAGAC-
TAAAT, respectively). The PCR products were cloned
into the pCR-TOPO vector (Invitrogen), and DNA
sequences were analyzed with the BLAST program.
Expression of FLRT2 in HEK293T cells
The full-length FLRT2 fragment was amplified by PCR
from genomic DNA of FLRT2-expressing YB2/0 clone
sorted as described earlier, by using Phusion High-Fidelity
DNA Polymerase (Finnzymes, Keilaranta, Espoo, Finland).
Primer sequences were as follows: 5’-CCCACCACATTG-
TATTTTATTTCC, 3’-CTTGATAACGCTGGGCCTCT.
The FLRT2 fragment was inserted into the pMX-IRES-
GFP vector (Cell Biolabs). An FLRT2 expression vector
with deletion of the unique region was made by using an
In-Fusion HD Cloning Kit (Clontech Laboratories, Madi-
son, WI, USA) with two PCR segments constructed to
omit the unique region (363 to 419 amino acids) and
inserted into the pMX-IRES-GFP vector. pMX-FLRT2-
IRES-GFP was transfected directly into HEK293T cells
with FuGENE HD (Roche Diagnostics, Basel, Switzerland)
or retrovirally transfected into HEK293T cells. Full-length
FLRT1 and FLRT3 fragments were amplified as described
earlier and inserted into the pMX-IRES-GFP vector.
Western blotting
Cells were lysed in RIPA buffer (Cell Signaling Technol-
ogy, Danvers, MA, USA). The lysate was mixed with 5 ×
sodium dodecyl sulfate (SDS) sample buffer and separated
by electrophoresis on an 8% polyacrylamide gel. The pro-
teins were then transferred onto Immobilon Transfer
Membranes (Millipore, Billerica, MA, USA). The mem-
branes were treated with 0.1 μg/ml of goat anti-FLRT2
antibody and IRDye680-conjugated donkey anti-goat IgG
(LI-COR Biosciences, Lincoln, NE, USA), and fluorescence
intensity was determined with the Odyssey Infrared Ima-
ging System (LI-COR).
CDC
CDC was assessed by the tetrazolium salt reduction
method by using WST-1 (Roche Diagnostics) [35-37]. In
brief, cells were seeded in 96-well culture plates at a con-
centration of 4 × 104 cells per well and cultured overnight.
Cells were incubated with 100 μl of diluted IgG for 30 min-
utes followed by addition of 50 μl of rabbit complement
(Cedarlane Laboratories, Burlington, ON, Canada) at the
indicated concentrations for 2 hours at 37°C. Then 15 μl
of WST-1 was added, and cells were incubated for an
additional 4 hours. Absorbance at 450 nm (A450) was mea-
sured and expressed as relative fluorescence units (RFUs),
reflecting the number of viable cells. Triton X-100 (1%)
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and heat-inactivated complement were added to the wells
to measure background or maximal absorbance of WST-
1, respectively. Recombinant FLRT2 was added in the inhi-
bition tests. The percentage cytotoxicity for each sample
was calculated by using the formula:
% cytotoxicity = (maximal RFU−sample RFU)/(maximal RFU−background RFU)×100.
ADCC
ADCC was determined by using the LDH Cytotoxicity
Detection Kit (Takara Bio) and the manufacturer’s pro-
tocol [36].
The percentage cytotoxicity was calculated as follows:
% cytotoxicity = (experimental−effector spontaneous −target spontaneous)/(target maximum−target spontaneous)×100.
Detection of adhesion molecule expression
HUVECs were cultured overnight in 96-well culture
plates and incubated with IgG (640 μg/ml) for 6 hours at
37°C. Harvested cells were stained with PE-conjugated
anti-CD62E antibody (BioLegend, San Diego, CA, USA),
allophycocyanin (APC)-conjugated anti-CD106 antibody
(BioLegend), and Pacific blue-conjugated anti-CD54
antibody (BioLegend), and were analyzed with flow
cytometry.
Detection of EC apoptosis
HUVECs were seeded in 48-well culture plates and incu-
bated with test IgG (640 μg/ml) for 24 hours, and apopto-
sis in the harvested cells was measured with annexin V
and 7-AAD (Apoptosis Detection Kit; BD Biosciences)
with flow cytometry. Annexin V-positive/7-AAD-negative
cells were measured as apoptotic cells.
Statistical analysis
Data were analyzed by using the two-tailed Student t test
or Mann-Whitney U test for continuous variables. Pair-
wise comparisons were assessed by using the Wilcoxon
signed-rank test. Spearman rank correlation was used to
explore the associations between anti-FLRT2 titer and
clinical parameters. All analyses were performed by using
Prism software (GraphPad Software, La Jolla, CA, USA).
In all analyses, P < 0.05 was taken to indicate statistical
significance.
Results
Detection of AECA activity with flow cytometry
We first examined AECA activity in the sera from patients
with collagen diseases by measuring binding activity of
IgG to nonpermeabilized 7-AAD-negative HUVECs by
using flow cytometry. The prevalence of AECAs was sig-
nificantly higher in patients with SLE (50.5%) and other
collagen diseases compared with normal controls (2.9%)
(Figure 1). As these data indicated the presence of autoan-
tigens on the EC surface, we constructed a retroviral vec-
tor system to identify cell-surface target molecules of
AECAs with flow cytometry.
Sorting of cells expressing cell-surface autoantigens with
retroviral vector system
Among sera with AECA activity, one sample (E10-19)
from an SLE patient with active lupus nephritis (WHO
IV) showed strong AECA activity (Figure 2A). We
selected this serum sample as the prototype of AECAs
for subsequent cell sorting. Purified IgG from E10-19
serum also showed strong binding to the surface of
HUVECs, and IgG from the same patient collected after
the treatment with 1 mg/kg prednisolone and intrave-
nous cyclophosphamide showed remarkably reduced
AECA activity (Figure 2A).
The YB2/0 cell line expressing HUVEC cDNA was gen-
erated by stable transfection of the HUVEC cDNA library
with the retroviral vector system. After staining of this cell
line with E10-19 IgG and FITC-conjugated secondary
antibody, cells with strong FITC signals were sorted with
flow cytometry. After cell expansion, we repeated one
more round of cell sorting to concentrate E10-19 IgG-
binding cells (Figure 2B). After the second sorting, cells
bound to E10-19 IgG were markedly increased, and several
cell clones were established from the E10-19 IgG-binding
cell population by the limiting dilution method. Two dis-
tinct clones with different E10-19 IgG-binding activities
and gene profiles of transfected HUVEC cDNA were
established, C9 and C18 (Figure 2C and 2D).
Identification of FLRT2 as a novel cell-surface autoantigen
After PCR amplification and cloning of HUVEC cDNA
inserted into the genomic DNA of C9 and C18, DNA
sequencing was performed followed by BLAST analysis.
PCR bands of around 3,000 bp in C9 and C18 (Figure 2D,
black box) were found to be an identical gene, that is,
fibronectin leucine-rich transmembrane protein 2 (FLRT2)
cDNA (GenBank accession number NM_013231.4). Real-
time quantitative PCR and microarray analysis of YB2/0,
C9, and C18 also supported the conclusion that only the
FLRT2 mRNA was overexpressed in both C9 and C18
(data not shown). Flow cytometry and Western blotting
showed that FLRT2 protein was expressed on the cell sur-
faces of C9 and C18 (Figure 3A). Next, we generated an
expression vector of FLRT2, which was transfected into
HEK293T cells. E10-19 IgG showed significant binding
activity to 7-AAD-negative FLRT2-expressing HEK293T
cells (Figure 3B), indicating that E10-19 IgG has high anti-
FLRT2 activity. Thus, the membrane protein FLRT2 was
identified as a novel autoantigen.
Flow cytometry and Western blotting indicated that
HUVECs and other ECs also expressed significant levels
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Figure 1 Distribution of antiendothelial cell antibodies (AECAs). The distribution of AECAs in collagen diseases was measured with flow
cytometry. Dots represent the data for individual subjects. The broken horizontal line indicates the cutoff value for high titers of AECAs (mean +
3 SD). Collagen diseases included systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), Sjögren syndrome (SS),
polymyositis (PM), dermatomyositis (DM), systemic sclerosis (SSc), rheumatoid arthritis (RA), antiphospholipid syndrome (APS), polyarteritis nodosa
(PN), Churg-Strauss syndrome (CSS), microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), giant cell arteritis (GCA), Takayasu
arteritis (TA), and Behçet disease (BD).
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Figure 2 Subcloning of autoantigen-expressing cells by using IgG from a patient with lupus nephritis. (A) Nonpermeabilized HUVECs
were stained with 1:10 diluted sera of control or E10-19 from a lupus nephritis patient (left), and 0.5 mg/ml of IgG of control or E10-19 collected
before (pre) or after (post) the treatments (right) followed by secondary antibody and analyzed with flow cytometry. (B) HUVEC cDNA-expressing
cells were stained with 0.5 mg/ml of E10-19 IgG followed by secondary antibody, and cells in the positive fraction were sorted (black dotted
box). Left indicates first sorting, and right indicates second sorting. (C) Unsorted and second-sorted cells (left), and unsorted and two clones
from second-sorted cells, C9 and C18, respectively (right), were stained with 0.5 mg/ml of E10-19 IgG followed by secondary antibody, and
analyzed with flow cytometry. (D) HUVEC cDNA fragments inserted into the genomic DNA of C9 and C18 were amplified, and PCR products
were electrophoresed on an 0.8% agarose gel.
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Figure 3 Identification of FLRT2 as a novel autoantigen of AECAs. (A) Unsorted, C9, and C18 were stained with isotype control or anti-
FLRT2 antibody, followed by secondary antibody, and analyzed with flow cytometry (left). Western blotting of proteins from unsorted, C9, and
C18 was performed, and they were stained with anti-FLRT2 antibody followed by secondary antibody (right). Arrows indicate the bands of
FLRT2. Both of the two bands are FLRT2 because some of FLRT2 proteins were glycosylated. (B) Expression vector, empty-IRES-GFP, or FLRT2-
IRES-GFP was transfected into HEK293T cells, and these cells were stained with 0.5 mg/ml of control IgG or E10-19 IgG, followed by secondary
antibody, and analyzed with flow cytometry. Binding activities of IgG to cell-surface FLRT2 were analyzed in histograms (right) by gating for the
GFP-positive transfected population (left). (C) HUVECs were stained with isotype control or anti-FLRT2 antibody followed by secondary antibody,
and analyzed with flow cytometry (left). Western blotting of proteins from HUVECs was performed, and they were stained with anti-FLRT2
antibody followed by secondary antibody (right). The arrows indicate the bands of FLRT2. (D) HAECs, HRGECs, and HMVEC-Ls were stained with
isotype control or anti-FLRT2 antibody followed by secondary antibody, and analyzed with flow cytometry. (E) HUVECs were stained with isotype
control, anti-FLRT1 antibody, or anti-FLRT3 antibody followed by secondary antibody, and analyzed with flow cytometry. (F) Expression vector,
FLRT1-IRES-GFP (left), or FLRT3-IRES-GFP (right) was transfected into HEK293T cells, and these cells were stained with 0.5 mg/ml of control IgG or
E10-19 IgG, followed by secondary antibody, and analyzed with flow cytometry.
Shirai et al. Arthritis Research & Therapy 2012, 14:R157
http://arthritis-research.com/content/14/4/R157
Page 6 of 13
of FLRT2 on their cell surfaces (Figure 3C, D). FLRT2 is
a member of the FLRT family, which includes FLRT1,
FLRT2, and FLRT3 [38]. We examined whether other
FLRTs were expressed on HUVECs with flow cytometry.
Neither FLRT1 nor FLRT3 was expressed on the surface
of these ECs, and E10-19 IgG showed no binding activ-
ity to either FLRT1 or FLRT3 (Figure 3E, F). These data
indicated that among the FLRT family, FLRT2 was the
only target molecule of AECAs.
Inhibition test and epitope mapping
We conducted inhibition tests to determine whether the
AECA activities of anti-FLRT2-positive SLE patients
were due to anti-FLRT2 activity. Incubation with soluble
recombinant FLRT2 inhibited the binding of patient IgG
to HUVECs (Figure 4A). We further investigated the epi-
tope of anti-FLRT2 antibody. FLRT2 contains extracellu-
lar leucine-rich repeats, unique region, fibronectin type
III domain, and a cytoplasmic tail. As mentioned earlier,
FLRT2 was the only member of the FLRT family that was
bound by SLE IgG, so we hypothesized that the unique
region of FLRT2 may be the major epitope for anti-
FLRT2 antibody. To investigate this hypothesis, an
expression vector of FLRT2 lacking the unique region
(FLRT2Δur) was generated. As shown in Figure 4B, the
binding activity of the anti-FLRT2 antibody was signifi-
cantly reduced when FLRT2 lacked its unique region (P
= 0.008) compared with the equal binding activity of
anti-FLRT2 antibody to the intracellular domain. These
observations indicated that the major epitope was loca-
lized within the unique region of FLRT2.
Distribution of patients with anti-FLRT2 activity
Anti-FLRT2 activities were detected in nine (10.2%) of 88
patients with SLE and one (6.7%) of 15 patients with
granulomatosis with polyangiitis (Wegener’s). Healthy
controls and other patients with collagen diseases,
including diseases that showed a high prevalence of
AECA activity, did not show anti-FLRT2 activity (Figure
5A). Strong anti-FLRT2 activities were detected in only
SLE patients, indicating that anti-FLRT2 antibody is spe-
cific to SLE patients. Among 48 SLE patients with AECA
positivity (Figure 1), 42 were examined for anti-FLRT2
activity, and nine patients (21.4%) were positive.
Among SLE patients with anti-FLRT2 positivity, anti-
FLRT2 activity was significantly correlated with low levels
of complement C3, C4, and CH50 (Figure 5B). No interre-
lations were found between anti-FLRT2 activity and the
SLE disease activity index (SLEDAI), anti-dsDNA antibody
titer, or serum amyloid A (SAA) level (Figure 5B).
A















Figure 4 Inhibition test and epitope mapping. (A) Inhibition tests of binding activities to HUVECs were performed by using IgG from healthy
donor (control) and anti-FLRT2 sera (X10-48) with soluble FLRT2 at the indicated concentrations. (B) Changes in binding activity to FLRT2 lacking
the unique region (Δur) compared with native FLRT2 were analyzed by using anti-FLRT2 sera. Representative dot plot (left) and a summary of
changes in each patient (right) are shown. Open circles show the binding activity to the intracellular FLRT2 domain.
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Induction of endothelial cell killing by CDC
We next assessed the functional significance of anti-
FLRT2 antibody by using IgG from the sera of two SLE
patients with high FLRT2 activity (B11-8 and X10-48).
IgG with anti-FLRT2 activity showed significant CDC
activity against HUVECs compared with IgG from nor-
mal controls (Figure 6A). This CDC activity was inhib-
ited by incubation with soluble recombinant FLRT2, and
increased with a higher concentration of IgG (Figure 6B,
C). Strong CDC activity was induced against FLRT2-
expressing HEK293T cells, but not against mock-trans-
fected HEK293T cells (Figure 6D). These observations
confirmed the ability of the anti-FLRT2 antibody to
induce CDC activity by binding to cell-surface FLRT2.
We also analyzed the IgG subclasses of anti-FLRT2
antibody with flow cytometry. In all anti-FLRT2 active
IgG subclasses, IgG1 and IgG2 activities were strong,
and IgG3 was weak. The presence of IgG4 varied
between patients (Figure 6E). Compared with IgG, weak
IgM activity was detected (Figure 6F). None of these
IgGs showed ADCC (Figure 6G).
Other pathogenic roles as AECAs
We examined further potentials for pathogenicity
against EC activation and induction of apoptosis. The
levels of expression of adhesion molecules (intercellular
adhesion molecule 1 (ICAM-1), vascular cell adhesion
molecule 1 (VCAM-1), and E-selectin) on HUVECs
were not increased by incubation with IgG purified
from B11-8 and X10-48 compared with control IgG
(Figure 7A). Incubation of HUVECs with anti-FLRT2-
positive IgG did not induce apoptosis (Figure 7B).
Discussion
Although the existence of AECAs in patients with SLE
and other collagen diseases has been reported, its patho-
genic significance remains unknown. The localization of















Figure 5 Distribution of patients with anti-FLRT2 activity. (A) The distribution of anti-FLRT2 activity in collagen diseases was measured with
flow cytometry. Dots represent the data for individual subjects. The broken horizontal line indicates the cutoff value for high anti-FLRT2 activity
(mean + 3SD). Collagen diseases included systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), Sjögren syndrome (SS),
polymyositis (PM), dermatomyositis (DM), systemic sclerosis (SSc), rheumatoid arthritis (RA), polyarteritis nodosa (PN), Churg-Strauss syndrome
(CSS), microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and Takayasu arteritis (TA). (B) Correlations of clinical parameters
with anti-FLRT2 activity among anti-FLRT2-positive SLE patients are shown. CH50, 50% hemolytic complement activity; SLEDAI, SLE disease
activity index; dsDNA Ab, anti-double-stranded DNA antibody; SAA, serum amyloid A.
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Figure 6 Complement-dependent cytotoxicity (CDC) of anti-FLRT2 antibody. CDC activities using two healthy control IgG and two anti-
FLRT2 positive IgG, B11-8 and X10-48, at a concentration of 1.28 mg/ml with 1:3 diluted complement (A), 1.28 mg/ml of IgG, and 1:3 diluted
complement with recombinant FLRT2 at the indicated concentrations (B), and various IgG concentrations with 1:6 diluted complement (C)
against HUVECs were measured with the WST-1 assay. (D) CDC activities against mock transfected HEK293T cells (empty, left) and FLRT2-
expressing HEK293T cells (FLRT2, right) by using 1.28 mg/ml of IgG and 1:3 diluted complement were measured with the WST-1 assay. HEK293T
cells negative or positive for FLRT2 expression were stained with anti-FLRT2 antibody followed by secondary antibody against human IgG1, IgG2,
IgG3, IgG4 (E), and IgM (F), and analyzed with flow cytometry. (G) ADCC activities using control IgG, B11-8, and X10-48, at a concentration of
1.28 mg/ml with an E:T ratio of 25:1 were determined with the lactate dehydrogenase detection method. Error bars indicate SD. *P < 0.05; **P <
0.01; ***P < 0.001; ****P < 0.0001.
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an important factor for its pathogenicity in vivo, in
terms of accessibility of the target molecule to AECAs.
Our strategy to identify AECA target molecules is to
use a retroviral vector system and flow cytometry. As
the localization of cellular molecules depends on their
structures, only cell-surface molecules are expressed on
the surface of YB2/0 cells transfected with the HUVEC
cDNA library. AECAs can bind only to cell-surface
molecules in flow cytometry. Therefore, sorting of IgG-
binding cells can concentrate and isolate cells expressing
autoantigens (target molecules for AECAs) on the cell
surface. Although this system may present difficulties in
sorting cells at very low frequency, we isolated and
cloned autoantigen-expressing cells by repeated sorting,
and this system was shown to be useful to identify cell-
surface autoantigens. Whereas some cell-surface mole-
cules were identified with this system previously [39],
this is the first report of autoantigen identification.
With purified IgG from one SLE patient with high
AECA activity (E10-19), two distinct clones were isolated
and established, both of which were shown to have an
identical gene, FLRT2. As we confirmed that E10-19 IgG
bound specifically to cell-surface FLRT2 and FLRT2 was
expressed on the cell surface of ECs, we concluded that
FLRT2 is a novel cell-surface autoantigen as a target
molecule for AECAs in SLE patients.
Analysis of anti-FLRT2 activity among patients with
various collagen diseases indicated that anti-FLRT2 anti-
body was specifically detected in SLE, and it accounted
for 21.4% of cell-surface target molecules of AECAs in
SLE. AECA activity of IgG from SLE patients with anti-
FLRT2 activity was significantly inhibited by soluble
recombinant FLRT2, indicating that FLRT2 is the major
target on ECs for AECAs in these patients. Although
heat-shock protein 60 (Hsp60) has been described as the
target antigen of AECAs in SLE and has a proapoptotic
effect [40,41], Hsp60 was not detected on freshly isolated
unstressed HUVECs [40,41]. The remaining 78.6% of
SLE patients with AECA activity in the present study
may have other as-yet-unidentified target antigens.
FLRT2 is transmembrane protein and was identified as
a novel gene family in the screening for extracellular
matrix proteins expressed in muscle [38]. Although
FLRT2 was shown to be expressed in the pancreas, skele-
tal muscle, brain, and heart with Northern blotting [38],
we confirmed the expression of FLRT2 on HUVECs and
other ECs (HAECs, HRGECs, and HMVEC-Ls), and
















control IgG B11-8 IgG X10-48 IgG
Figure 7 Activation of HUVECs and induction of apoptosis. (A) Expression of E-selectin, intercellular adhesion molecule 1 (ICAM-1), and
vascular cell adhesion molecule 1 (VCAM-1) was analyzed with flow cytometry against HUVECs treated with 640 μg/ml of control and two anti-
FLRT2-positive IgGs, B11-8 and X10-48. Representative graphs (left) and summarized graph (right) are shown. (B) HUVECs treated with control
IgG and two anti-FLRT2-positive IgGs, B11-8 and X10-48, for 24 hours were stained with annexin V and 7-AAD and analyzed with flow cytometry.
(Annexin V positive/7-AAD negative) cells were measured as apoptotic cells. Representative graphs (left) and summarized graph (right) are
shown. Error bars indicate SD.
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nor lipopolysaccharide (LPS) induced the expression of
FLRT2 (data not shown). E10-19 IgG did not bind to
FLRT1 and FLRT3, and these two molecules were not
expressed on ECs. Consistent with these findings, the
major epitope for anti-FLRT2 antibody was localized in
the unique region within the extracellular domain of
FLRT2.
FLRT2 has been reported to modulate signaling, interact
with fibroblast growth factor receptor, promote cell prolif-
eration, participate in craniofacial development, and pro-
mote heart morphogenesis [42-46]. Although we
hypothesized that anti-FLRT2 antibody may affect some
cellular behavior and induce expression of adhesion mole-
cules, cell proliferation, and apoptotic cell death without
complement in ECs, we did not find these activities in the
present study.
Among SLE patients with anti-FLRT2 activity, comple-
ment levels were correlated significantly with the anti-
FLRT2 antibody titer. Moreover, anti-FLRT2 antibody
induced cell damage in a complement-dependent manner,
suggesting that it has pathogenic roles in immune-
mediated vascular damage. CDC activity of AECAs was
reported in patients with SLE, Takayasu arteritis, hemoly-
tic-uremic syndrome, and Kawasaki disease [2,4,35,47,48].
Although ADCC activity was not proven in our study,
similar observations of AECAs producing CDC but not
ADCC were reported previously [35,48].
As demonstrated in this study, FLRT2 is widely distribu-
ted in various types of ECs. Therefore, it is possible that
anti-FLRT2 antibody is linked to systemic vascular injury.
These observations indicate that it is necessary to evaluate
the contributions of anti-FLRT2 antibody to atherosclero-
tic lesions because chronic inflammation is atherogenic
in SLE [49,50]. Administration of gammaglobulin was
reported to reduce CDC of AECAs against ECs [35], and
this may apply to anti-FLRT2 antibody-induced damage.
Furthermore, incubation with soluble recombinant FLRT2
inhibited the AECA activity and CDC activity in patients
with anti-FLRT2 positivity, which suggests that neutraliz-
ing anti-FLRT2 antibodies might be the specific therapeu-
tic approach.
Conclusions
We identified the membrane protein FLRT2 as a novel
autoantigen of AECAs in SLE patients. Our retroviral
vector system is useful for identification of cell-surface
autoantigens. In addition to further investigations of the
biologic significance of anti-FLRT2 antibody and its
therapeutic applications, other cell-surface autoantigens
of AECAs should be determined to achieve a compre-
hensive understanding of AECA-mediated vascular
injury and the development of more-specific interven-
tion strategies.
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